Tremelimumab: tested in a combination
143 studies: another drug in the study is under test too. Page 1 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- IIT2025-03-YANG-LIFT-HCCRecruitingNCT07489976Phase 2Report a problem
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2Report a problem
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingNCT07174570Phase 2Report a problem
- Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingNCT07122089Phase 2Report a problem
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.RecruitingNCT07027436Phase 3Report a problem
- Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999707Phase 2Report a problem
- Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999694Phase 2Report a problem
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingNCT06921785Phase 3Report a problem
- Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruitingNCT06911255Phase 1/2Report a problem
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2Report a problem
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingNCT06824363Early Phase 1Report a problem
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingNCT06526104Phase 2Report a problem
- HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCCRecruitingNCT06364007Phase 2Report a problem
- Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNomaRecruitingNCT06341764Phase 2Report a problem
- Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT06058663Phase 1Report a problem
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for MesotheliomaRecruitingNCT05932199Phase 1/2Report a problem
- HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2Report a problem
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2Report a problem
- Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2Report a problem
- Durvalumab and Tremelimumab in Resectable HCCRecruitingNCT05440864Phase 2Report a problem
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingNCT04585490Phase 3Report a problem
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingNCT04430452Phase 2Report a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1Report a problem
- A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingNCT03847649Phase 2Report a problem
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingNCT03539822Phase 1/2Report a problem
- Renal Adjuvant MultiPle Arm Randomised TrialRecruitingNCT03288532Phase 3Report a problem
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2Report a problem
- Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)TerminatedNCT04989218Phase 1/2Results postedReport a problem
- Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results postedReport a problem
- Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results postedReport a problem
- Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractCompletedNCT03430895Phase 2Results postedReport a problem
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT03298451Phase 3Results postedReport a problem
- Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerTerminatedNCT03237377Phase 2Results postedReport a problem
- Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingNCT03164616Phase 3Results postedReport a problem
- A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal CancerCompletedNCT03122509Phase 2Results postedReport a problem
- Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginCompletedNCT03095274Phase 2Results postedReport a problem
- An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.CompletedNCT03084471Phase 3Results postedReport a problem
- A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminatedNCT03075527Phase 2Results postedReport a problem
- Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active, not recruitingNCT03043872Phase 3Results postedReport a problem
- A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerCompletedNCT03015129Phase 2Results postedReport a problem
- Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results postedReport a problem
- A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results postedReport a problem
- Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic AdenocarcinomaCompletedNCT02879318Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab in Patients With Advanced Rare TumoursCompletedNCT02879162Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal CancerCompletedNCT02870920Phase 2Results postedReport a problem
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results postedReport a problem
- Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesCompletedNCT02815995Phase 2Results postedReport a problem
- Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant GliomaCompletedNCT02794883Phase 2Results postedReport a problem
- Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate CancerCompletedNCT02788773Phase 2Results postedReport a problem
- Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryCompletedNCT02754856Phase 1Results postedReport a problem
- Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerCompletedNCT02735239Phase 1/2Results postedReport a problem
- Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantTerminatedNCT02716805Phase 1Results postedReport a problem
- Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung CancerCompletedNCT02701400Phase 2Results postedReport a problem
- A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results postedReport a problem
- MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural MesotheliomaCompletedNCT02592551Phase 2Results postedReport a problem
- Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal CarcinomaCompletedNCT02558894Phase 2Results postedReport a problem
- Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck CancerCompletedNCT02551159Phase 3Results postedReport a problem
- Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active, not recruitingNCT02542293Phase 3Results postedReport a problem
- MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerCompletedNCT02536794Phase 2Results postedReport a problem
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results postedReport a problem
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerActive, not recruitingNCT02516241Phase 3Results postedReport a problem
- Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results postedReport a problem
- Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck CancerCompletedNCT02369874Phase 3Results postedReport a problem
- A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02352948Phase 3Results postedReport a problem
- A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaCompletedNCT02340975Phase 1/2Results postedReport a problem
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and NeckCompletedNCT02319044Phase 2Results postedReport a problem
- Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results postedReport a problem
- Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results postedReport a problem
- A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabCompletedNCT01975831Phase 1Results postedReport a problem
- Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV MelanomaCompletedNCT00610857Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2Report a problem
- A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular CarcinomaWithdrawnNCT06994299Phase 2Report a problem
- Single cEll pRofiling PErsistaNce To ImmuNothErapyActive, not recruitingNCT06680739Phase 2Report a problem
- Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation ProcedureActive, not recruitingNCT06045975Phase 2Report a problem
- Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2Report a problem
- A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2Report a problem
- Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3Report a problem
- SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruitingNCT05701488Phase 1Report a problem
- Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3Report a problem
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)Active, not recruitingNCT05451043Phase 2Report a problem
- Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)WithdrawnNCT05383001Phase 2Report a problem
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3Report a problem
- TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2Report a problem
- Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3Report a problem
- Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentWithdrawnNCT04625699Phase 2Report a problem
- Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive, not recruitingNCT04395079Phase 2Report a problem
- Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)Active, not recruitingNCT04238637Phase 2Report a problem
- Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT04221555Phase 2Report a problem
- RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusActive, not recruitingNCT04159974Phase 2Report a problem
- A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)Status unknownNCT03975114Phase 2Report a problem
- Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT03965468Phase 2Report a problem
- A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCTerminatedNCT03963414Phase 1Report a problem
- Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaActive, not recruitingNCT03959293Phase 2Report a problem
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2Report a problem
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1Report a problem
- Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsCompletedNCT03911557Phase 2Report a problem
- Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver MetastasesWithdrawnNCT03802747Phase 1Report a problem
- Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT03784066Phase 1/2Report a problem
- Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Status unknownNCT03737968Phase 2Report a problem
- An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2Report a problem